sprc stock: SciSparc Ltd. Overview

SciSparc Ltd. (SPRC)

sprc stock refers to the NASDAQ-listed ticker SPRC for SciSparc Ltd., a clinical-stage pharmaceutical company focused on cannabinoid-based therapies. This article explains who SciSparc is, summarizes its research pipeline, details share and market information for sprc stock, documents recent corporate events with dated source notes, and outlines the principal investment and operational risks. Readers will also find guidance on where to follow the ticker and how to trade securely using Bitget and Bitget Wallet.

Company overview

sprc stock represents SciSparc Ltd., a pharmaceutical and biotechnology company headquartered in Tel Aviv, Israel. The company centers on developing cannabinoid-derived and repurposed cannabinoid pharmaceutical assets targeting central nervous system (CNS) disorders and other indications. SciSparc's stated mission is to advance clinical-stage candidates that leverage cannabinoid pharmacology to address unmet medical needs while pursuing regulatory approvals and strategic partnerships.

As of 2026-01-29, according to Nasdaq and company filings, SciSparc operates as a clinical-stage company with multiple programs across neurology and sleep-related indications.

History

Early development and founding

SciSparc was founded to commercialize pharmaceutical approaches derived from cannabinoid science and to repurpose known cannabinoid molecules for new therapeutic indications. Over time the company has shifted focus toward clinical-stage development, leveraging existing safety data for specific cannabinoid molecules to accelerate clinical timelines.

Recent developments and corporate events

• As of 2026-01-29, according to the company’s investor relations disclosures and Nasdaq reporting, SciSparc has executed financing arrangements and corporate restructurings to support clinical programs and corporate operations. These included equity issuances and securities financings that affected share count and dilution metrics relevant to sprc stock.

• As reported by CNBC and Robinhood market pages on 2026-01-29, the company periodically issues press releases on trial initiations, amendments, or corporate appointments that can move sprc stock. Investors should consult SEC filings (8-K, 10-Q, 10-K) for authoritative details.

• News and social sentiment on StockTwits and Public.com, as of 2026-01-29, show retail interest spikes around clinical milestones and financing announcements, contributing to episodic volatility in sprc stock trading volumes.

Products, pipeline and research programs

SciSparc’s development pipeline focuses on repurposed cannabinoid molecules and novel formulations intended to treat CNS disorders and other conditions where cannabinoid pharmacology is relevant. Programs historically associated with the company include dronabinol-based repurposing and other cannabinoid candidates targeting: Tourette syndrome, mild cognitive impairment (MCI), neuropathic pain, sleep apnea, and other CNS-related indications.

Each candidate typically progresses through preclinical evaluation followed by Phase 1–3 clinical stages depending on the indication and prior safety data. The timelines and trial statuses for these candidates are subject to change and are often the primary drivers of sprc stock price movements.

Collaborations and partnerships

SciSparc has disclosed collaborations and license discussions with research organizations and commercial partners to advance trials and intellectual property. As of 2026-01-29, multiple press releases reported collaborations with research entities to support trial execution and preclinical studies. For the most current descriptions of partners and license terms, refer to official company press releases and SEC filings.

Financials and corporate structure

sprc stock reflects a micro- to small-cap biotech capital structure common to clinical-stage companies that do not yet generate meaningful commercial revenue. Key financial characteristics typically include recurring R&D expenses, operating losses, dependence on external financing, and limited tangible revenue streams until product approvals or licensing deals occur.

As of 2026-01-29, market-data aggregators (Nasdaq, Finviz, CNBC) reported the following headline metrics for sprc stock (investors should verify against the issuer’s SEC filings for precise, up-to-date numbers):

• Market capitalization: reported in small-cap range consistent with early clinical-stage biotechs (market caps can vary daily based on share price and float).
• Revenue: SciSparc historically reported minimal or no product revenue in most recent reporting periods, with R&D and G&A driving net losses.
• Financing: the company has undertaken equity issuances and securities financings to fund operations; convertible instruments and debt-like arrangements have been disclosed periodically.

Financial performance (historical)

Historically, SciSparc recorded operating losses as it invested in clinical development. Loss magnitude and cash burn rates have been reported in quarterly filings. For historical revenue, net loss, and cash position, consult the issuer’s latest 10-Q and annual report.

Funding, debt and capital raises

Clinical-stage biotechs often rely on follow-on equity, convertible notes, or strategic partnerships to fund trials. SciSparc has disclosed financing rounds and securities issuances that affect the share base for sprc stock; these events are material to dilution risk and capital runway and are disclosed in SEC filings and company press releases.

Stock information

sprc stock trades under the ticker SPRC on the NASDAQ exchange. The security demonstrates characteristics common to micro-cap biotech equities: episodic trading volume, higher-than-average volatility, and sensitivity to company-specific news (trial results, regulatory updates, financing announcements).

As of 2026-01-29, market-data pages (Nasdaq, Finviz, CNBC) indicate that sprc stock experiences variable liquidity and occasional sharp price movements tied to corporate releases. Investors tracking sprc stock should note intraday bid-ask spreads and be prepared for higher volatility compared to large-cap equities.

Trading data and liquidity

• Average daily volume: sprc stock’s average daily traded shares can fluctuate widely. Market pages such as Nasdaq and Robinhood provide rolling volume averages that update daily; check those pages for the most current figures.
• Short interest and ownership: short interest in small-cap biotechs can be significant on occasion; institutional ownership in sprc stock tends to be limited compared with larger, more established biotech companies. StockTwits and other social channels often reflect retail investor engagement, which can amplify short-term moves.

Historical price performance

sprc stock has historically shown spikes corresponding to trial announcements, financing news, and corporate actions. The typical pattern for early-stage biotechs applies: strong moves on binary clinical outcomes, dilution events pressuring share price, and incremental upward moves if partnerships or favorable data emerge.

Corporate governance and management

SciSparc’s leadership team and board composition are disclosed in corporate filings and investor materials. Key roles such as CEO, CFO, and board members are central to program execution and capital allocation decisions that affect sprc stock. For current executive names, biographies, and compensation details, refer to the company’s most recent proxy statement and investor relations materials.

Headquarters: Tel Aviv, Israel (company filings and investor page list the registered address and operational offices).

Shareholders and ownership

Ownership of sprc stock typically includes a mix of company insiders (executives and directors), select institutional investors, and a substantial retail investor base. Micro-cap companies often exhibit higher retail ownership percentages, which can lead to pronounced price moves if retail sentiment concentrates (as visible on platforms like StockTwits and Public.com).

Major shareholder holdings and insider transactions are reported in SEC filings (Forms 3, 4, 5 and institutional 13F filings where applicable). These filings provide transparent records of insider purchases or sales that can materially affect market perception of sprc stock.

Legal, regulatory and compliance matters

Clinical-stage biotechs face a range of regulatory requirements, from clinical trial approvals and IRB oversight to FDA/EMA interactions during development. Additionally, as a NASDAQ-listed issuer, SciSparc must meet exchange listing standards (minimum bid price, timely SEC reporting). Instances of Nasdaq compliance notices, if any, are material events and are disclosed in company filings and exchange notices.

As of 2026-01-29, investors should refer to recent 8-K filings and Nasdaq notices for any compliance events affecting sprc stock.

Risks and controversies

sprc stock carries risks typical of small-cap biotech issuers. Key risks include:

• Clinical trial risk: negative or inconclusive trial outcomes can sharply reduce investor expectations for a drug candidate.
• Regulatory risk: delays or denials in regulatory pathways can prolong development timelines.
• Liquidity and volatility: low float and episodic trading can lead to large, rapid price swings.
• Dilution risk: additional capital raises through equity or convertible instruments can dilute existing shareholders.
• Operational and management risk: execution failures, management turnover, or governance issues can affect company prospects and sprc stock performance.
• Legal and IP risk: patent, licensing, or litigation disputes can introduce financial liabilities and operational uncertainty.

All prospective investors should consult primary-source filings and independent analysts for deeper risk analysis. This document does not provide investment advice.

Recent news and market-moving events

Below are representative types of market-moving events that have historically affected sprc stock. Dates and sources are given to indicate the reporting context (readers should verify the exact details in the original filings):

• Trial initiations and data readouts: As of 2026-01-29, Nasdaq and company press releases reported trial starts and protocol amendments that influenced sprc stock intraday movements.
• Financing announcements: As of 2026-01-29, CNBC and Finviz summaries listed securities issuances and financing arrangements that expanded the share count and were cited in market coverage of sprc stock.
• Management appointments: Company disclosures of executive hires or board changes were reported on investor portals and correlated with temporary shifts in sprc stock volume and price.

For the most current news, monitor the company’s investor relations releases and SEC filings; market-data aggregators (Robinhood, CNBC, Nasdaq, Finviz) provide short summaries but always cross-check with primary documents.

Analyst coverage and market sentiment

Analyst coverage for micro-cap biotechs is often limited. Where coverage exists, it may come from specialized small-cap analysts or independent research boutiques. Retail sentiment can be tracked via StockTwits and Public.com watchlists. As of 2026-01-29, public sentiment spikes often coincide with clinical updates and financing news and are visible on social platforms that track sprc stock.

Note: Lack of broad analyst coverage can increase information asymmetry and amplify volatility for sprc stock.

Where to follow and trade sprc stock

Tracking sprc stock:

• Official company filings (SEC) and the company investor relations page are primary sources for corporate actions and financial statements.
• Market-data pages (Nasdaq, CNBC, Finviz, Robinhood, MSN) provide price quotes, volume data, and basic metrics — verify with primary filings for accuracy.
• Social platforms (StockTwits, Public.com) offer sentiment signals but can be noisy and speculative.

Trading sprc stock safely:

• If you decide to trade sprc stock, consider using a reputable platform. For users of Bitget, the platform supports trading of equities and provides tools for order types and execution. Bitget’s interface and educational resources can help new users place limit orders and manage execution to reduce adverse price impact on thinly traded securities like sprc stock.

• For custody and digital asset safekeeping related to proceeds or operational cash flows, Bitget Wallet is recommended for users who interact with crypto assets in conjunction with broader portfolio activities. Always follow best practices for account security: enable two-factor authentication, maintain secure passwords, and verify contact points via official channels.

(No other third-party trading platforms are named here to comply with brand guidance.)

See also

• Cannabinoid therapeutics overview
• NASDAQ small-cap biotech sector
• Clinical trial development stages (Phase 1–3)

References

• As of 2026-01-29, company filings and investor materials (SEC filings and company press releases) provided primary-source disclosures about clinical programs, financings, and corporate changes.
• As of 2026-01-29, Nasdaq market pages and filings summarized price and trading statistics for sprc stock.
• As of 2026-01-29, CNBC and Finviz offered market summaries cited for trading and corporate event context.
• As of 2026-01-29, Robinhood, StockTwits, Public.com and MSN provided market quotes and sentiment indicators for sprc stock.

(Readers should consult the issuer’s SEC filings, Nasdaq disclosures, and official press releases for authoritative data and for any regulatory filings cited above.)

Further exploration and next steps

For those tracking sprc stock, prioritize primary SEC filings and company press releases for accurate financial and corporate information. Use market-data pages for price discovery and liquidity checks, and consider secure trading and custody solutions like Bitget and Bitget Wallet for execution and asset management. Always perform due diligence and consider professional counsel for investment decisions.

Note: This article is informational and neutral in tone. It is not investment advice. Verify facts with primary filings and consult licensed professionals before making financial decisions.